Prothena (NASDAQ:PRTA) Earns Buy Rating from Chardan Capital
Chardan Capital reiterated their buy rating on shares of Prothena (NASDAQ:PRTA – Free Report) in a report released on Friday,Benzinga reports. The brokerage currently has a $40.00 price objective on the biotechnology company’s stock. Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of […]
More Stories
Iran Declares Strait of Hormuz Open, but Warns of Risk From Mines
By Chris Summers Iran said on April 9 that the Strait of Hormuz is open to all civilian shipping but...
Remote-Job Postings Rise 20 Percent Sequentially in 1st Quarter: Report
By Mary Prenon Although many American companies, both large and small, have called employees back to the office over the...
Updates on XO, Kitty Season 4 Renewal: Release Date, Cast, and Spoiler
Netflix’s popular romantic comedy drama, XO, Kitty is back with all new connections and a story. The American television drama...
US State Department Issues Travel Advisory for 3 African Nations
By Naveen Athrappully The U.S. Department of State recently issued travel advisories for Nigeria, Ethiopia, and São Tomé and Príncipe,...
US Forces Will Remain in Region Until Iran Complies With Agreement: Trump
By Victoria Friedman U.S. President Donald Trump said on April 8 that warships and personnel will remain in the region...
Homeward Bound: Artemis II Leaves Lunar Space, Reveals ‘Earthset’ Photos
By T.J. Muscaro HOUSTON—The Artemis II astronauts are on their way home from the moon. NASA’s Reid Wiseman, Victor Glover,...